TY - JOUR AU - Foley, R. N. AU - Parfrey, P. S. AU - Sarnak, M. J. PY - 1998 DA - 1998// TI - Epidemiology of cardiovascular disease in chronic renal disease JO - J Am Soc Nephrol VL - 9 ID - Foley1998 ER - TY - JOUR AU - Masakane, I. AU - Nakai, S. AU - Ogata, S. AU - Kimata, N. AU - Hanafusa, N. AU - Hamano, T. PY - 2015 DA - 2015// TI - An overview of regular dialysis treatment in japan (As of 31 December 2013) JO - Ther Apher Dial VL - 19 UR - https://doi.org/10.1111/1744-9987.12378 DO - 10.1111/1744-9987.12378 ID - Masakane2015 ER - TY - JOUR AU - Pitt, B. AU - Zannad, F. AU - Remme, W. J. AU - Cody, R. AU - Castaigne, A. AU - Perez, A. PY - 1999 DA - 1999// TI - The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators JO - N Engl J Med VL - 341 UR - https://doi.org/10.1056/NEJM199909023411001 DO - 10.1056/NEJM199909023411001 ID - Pitt1999 ER - TY - JOUR AU - Zannad, F. AU - McMurray, J. J. AU - Krum, H. AU - Veldhuisen, D. J. AU - Swedberg, K. AU - Shi, H. PY - 2011 DA - 2011// TI - Eplerenone in patients with systolic heart failure and mild symptoms JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1009492 DO - 10.1056/NEJMoa1009492 ID - Zannad2011 ER - TY - JOUR AU - Pitt, B. AU - Remme, W. AU - Zannad, F. AU - Neaton, J. AU - Martinez, F. AU - Roniker, B. PY - 2003 DA - 2003// TI - Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa030207 DO - 10.1056/NEJMoa030207 ID - Pitt2003 ER - TY - JOUR AU - Pitt, B. AU - Reichek, N. AU - Willenbrock, R. AU - Zannad, F. AU - Phillips, R. A. AU - Roniker, B. PY - 2003 DA - 2003// TI - Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study JO - Circulation VL - 108 UR - https://doi.org/10.1161/01.CIR.0000091405.00772.6E DO - 10.1161/01.CIR.0000091405.00772.6E ID - Pitt2003 ER - TY - JOUR AU - Greenblatt, D. J. AU - Koch-Weser, J. PY - 1973 DA - 1973// TI - Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program JO - JAMA VL - 225 UR - https://doi.org/10.1001/jama.1973.03220280028007 DO - 10.1001/jama.1973.03220280028007 ID - Greenblatt1973 ER - TY - JOUR AU - Kushner, F. G. AU - Hand, M. AU - Smith, S. C. AU - King, S. B. AU - Anderson, J. L. AU - Antman, E. M. PY - 2009 DA - 2009// TI - 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines JO - Circulation VL - 120 UR - https://doi.org/10.1161/CIRCULATIONAHA.109.192663 DO - 10.1161/CIRCULATIONAHA.109.192663 ID - Kushner2009 ER - TY - JOUR AU - Lumb, G. AU - Newberne, P. AU - Rust, J. H. AU - Wagner, B. PY - 1978 DA - 1978// TI - Effects in animals of chronic administration of spironolactone—a review JO - J Environ Pathol Toxicol VL - 1 ID - Lumb1978 ER - TY - JOUR AU - Struthers, A. D. PY - 1996 DA - 1996// TI - Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure JO - J Card Fail VL - 2 UR - https://doi.org/10.1016/S1071-9164(96)80009-1 DO - 10.1016/S1071-9164(96)80009-1 ID - Struthers1996 ER - TY - JOUR AU - Barr, C. S. AU - Lang, C. C. AU - Hanson, J. AU - Arnott, M. AU - Kennedy, N. AU - Struthers, A. D. PY - 1995 DA - 1995// TI - Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease JO - Am J Cardiol VL - 76 UR - https://doi.org/10.1016/S0002-9149(99)80353-1 DO - 10.1016/S0002-9149(99)80353-1 ID - Barr1995 ER - TY - JOUR AU - Ponda, M. P. AU - Hostetter, T. H. PY - 2006 DA - 2006// TI - Aldosterone antagonism in chronic kidney disease JO - Clin J Am Soc Nephrol VL - 1 UR - https://doi.org/10.2215/CJN.00120106 DO - 10.2215/CJN.00120106 ID - Ponda2006 ER - TY - JOUR AU - Laragh, J. H. PY - 1973 DA - 1973// TI - Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles JO - Am J Med VL - 55 UR - https://doi.org/10.1016/0002-9343(73)90128-9 DO - 10.1016/0002-9343(73)90128-9 ID - Laragh1973 ER - TY - JOUR AU - Tanabe, A. AU - Naruse, M. AU - Naruse, K. AU - Hase, M. AU - Yoshimoto, T. AU - Tanaka, M. PY - 1997 DA - 1997// TI - Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension JO - Hypertens Res VL - 20 UR - https://doi.org/10.1291/hypres.20.85 DO - 10.1291/hypres.20.85 ID - Tanabe1997 ER - TY - JOUR AU - Coirini, H. AU - Magarinos, A. M. AU - Nicola, A. F. AU - Rainbow, T. C. AU - McEwen, B. S. PY - 1985 DA - 1985// TI - Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro JO - Brain Res VL - 361 UR - https://doi.org/10.1016/0006-8993(85)91291-0 DO - 10.1016/0006-8993(85)91291-0 ID - Coirini1985 ER - TY - JOUR AU - Kornel, L. PY - 1994 DA - 1994// TI - Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells JO - Am J Hypertens VL - 7 ID - Kornel1994 ER - TY - JOUR AU - Bonvalet, J. P. AU - Alfaidy, N. AU - Farman, N. AU - Lombes, M. PY - 1995 DA - 1995// TI - Aldosterone: intracellular receptors in human heart JO - Eur Heart J VL - 16 UR - https://doi.org/10.1093/eurheartj/16.suppl_N.92 DO - 10.1093/eurheartj/16.suppl_N.92 ID - Bonvalet1995 ER - TY - JOUR AU - Robert, V. AU - Silvestre, J. S. AU - Charlemagne, D. AU - Sabri, A. AU - Trouve, P. AU - Wassef, M. PY - 1995 DA - 1995// TI - Biological determinants of aldosterone-induced cardiac fibrosis in rats JO - Hypertension VL - 26 UR - https://doi.org/10.1161/01.HYP.26.6.971 DO - 10.1161/01.HYP.26.6.971 ID - Robert1995 ER - TY - JOUR AU - Delcayre, C. AU - Swynghedauw, B. PY - 2002 DA - 2002// TI - Molecular mechanisms of myocardial remodeling. The role of aldosterone JO - J Mol Cell Cardiol VL - 34 UR - https://doi.org/10.1006/jmcc.2002.2088 DO - 10.1006/jmcc.2002.2088 ID - Delcayre2002 ER - TY - JOUR AU - Duprez, D. AU - Buyzere, M. AU - Rietzschel, E. R. AU - Clement, D. L. PY - 2000 DA - 2000// TI - Aldosterone and vascular damage JO - Curr Hypertens Rep VL - 2 UR - https://doi.org/10.1007/s11906-000-0017-z DO - 10.1007/s11906-000-0017-z ID - Duprez2000 ER - TY - JOUR AU - Farquharson, C. A. AU - Struthers, A. D. PY - 2000 DA - 2000// TI - Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure JO - Circulation VL - 101 UR - https://doi.org/10.1161/01.CIR.101.6.594 DO - 10.1161/01.CIR.101.6.594 ID - Farquharson2000 ER - TY - JOUR AU - Sun, Y. AU - Zhang, J. AU - Lu, L. AU - Chen, S. S. AU - Quinn, M. T. AU - Weber, K. T. PY - 2002 DA - 2002// TI - Aldosterone-induced inflammation in the rat heart : role of oxidative stress JO - Am J Pathol VL - 161 UR - https://doi.org/10.1016/S0002-9440(10)64454-9 DO - 10.1016/S0002-9440(10)64454-9 ID - Sun2002 ER - TY - JOUR AU - Rocha, R. AU - Martin-Berger, C. L. AU - Yang, P. AU - Scherrer, R. AU - Delyani, J. AU - McMahon, E. PY - 2002 DA - 2002// TI - Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart JO - Endocrinology VL - 143 UR - https://doi.org/10.1210/en.2002-220120 DO - 10.1210/en.2002-220120 ID - Rocha2002 ER - TY - JOUR AU - Nagata, K. AU - Obata, K. AU - Xu, J. AU - Ichihara, S. AU - Noda, A. AU - Kimata, H. PY - 2006 DA - 2006// TI - Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats JO - Hypertension VL - 47 UR - https://doi.org/10.1161/01.HYP.0000203772.78696.67 DO - 10.1161/01.HYP.0000203772.78696.67 ID - Nagata2006 ER - TY - JOUR AU - Struthers, A. D. AU - MacDonald, T. M. PY - 2004 DA - 2004// TI - Review of aldosterone- and angiotensin II-induced target organ damage and prevention JO - Cardiovasc Res VL - 61 UR - https://doi.org/10.1016/j.cardiores.2003.11.037 DO - 10.1016/j.cardiores.2003.11.037 ID - Struthers2004 ER - TY - JOUR AU - Fujita, T. PY - 2008 DA - 2008// TI - Aldosterone in salt-sensitive hypertension and metabolic syndrome JO - J Mol Med (Berl) VL - 86 UR - https://doi.org/10.1007/s00109-008-0343-1 DO - 10.1007/s00109-008-0343-1 ID - Fujita2008 ER - TY - JOUR AU - Brilla, C. G. AU - Pick, R. AU - Tan, L. B. AU - Janicki, J. S. AU - Weber, K. T. PY - 1990 DA - 1990// TI - Remodeling of the rat right and left ventricles in experimental hypertension JO - Circ Res VL - 67 UR - https://doi.org/10.1161/01.RES.67.6.1355 DO - 10.1161/01.RES.67.6.1355 ID - Brilla1990 ER - TY - JOUR AU - Lombes, M. AU - Oblin, M. E. AU - Gasc, J. M. AU - Baulieu, E. E. AU - Farman, N. AU - Bonvalet, J. P. PY - 1992 DA - 1992// TI - Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor JO - Circ Res VL - 71 UR - https://doi.org/10.1161/01.RES.71.3.503 DO - 10.1161/01.RES.71.3.503 ID - Lombes1992 ER - TY - JOUR AU - Schiffrin, E. L. PY - 2006 DA - 2006// TI - Effects of aldosterone on the vasculature JO - Hypertension VL - 47 UR - https://doi.org/10.1161/01.HYP.0000201443.63240.a7 DO - 10.1161/01.HYP.0000201443.63240.a7 ID - Schiffrin2006 ER - TY - JOUR AU - Belle, E. AU - Bauters, C. AU - Wernert, N. AU - Hamon, M. AU - McFadden, E. P. AU - Racadot, A. PY - 1995 DA - 1995// TI - Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, and aldosterone antagonist JO - Cardiovasc Res VL - 29 UR - https://doi.org/10.1016/S0008-6363(96)88542-7 DO - 10.1016/S0008-6363(96)88542-7 ID - Belle1995 ER - TY - JOUR AU - Sawathiparnich, P. AU - Kumar, S. AU - Vaughan, D. E. AU - Brown, N. J. PY - 2002 DA - 2002// TI - Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans JO - J Clin Endocrinol Metab VL - 87 UR - https://doi.org/10.1210/jcem.87.2.7980 DO - 10.1210/jcem.87.2.7980 ID - Sawathiparnich2002 ER - TY - JOUR AU - Dinh, Q. N. AU - Young, M. J. AU - Evans, M. A. AU - Drummond, G. R. AU - Sobey, C. G. AU - Chrissobolis, S. PY - 2016 DA - 2016// TI - Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor JO - Brain Res VL - 1637 UR - https://doi.org/10.1016/j.brainres.2016.02.034 DO - 10.1016/j.brainres.2016.02.034 ID - Dinh2016 ER - TY - JOUR AU - Leopold, J. A. AU - Dam, A. AU - Maron, B. A. AU - Scribner, A. W. AU - Liao, R. AU - Handy, D. E. PY - 2007 DA - 2007// TI - Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity JO - Nat Med VL - 13 UR - https://doi.org/10.1038/nm1545 DO - 10.1038/nm1545 ID - Leopold2007 ER - TY - JOUR AU - Nagata, D. AU - Takahashi, M. AU - Sawai, K. AU - Tagami, T. AU - Usui, T. AU - Shimatsu, A. PY - 2006 DA - 2006// TI - Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity JO - Hypertension VL - 48 UR - https://doi.org/10.1161/01.HYP.0000226054.53527.bb DO - 10.1161/01.HYP.0000226054.53527.bb ID - Nagata2006 ER - TY - JOUR AU - Rajagopalan, S. AU - Duquaine, D. AU - King, S. AU - Pitt, B. AU - Patel, P. PY - 2002 DA - 2002// TI - Mineralocorticoid receptor antagonism in experimental atherosclerosis JO - Circulation VL - 105 UR - https://doi.org/10.1161/01.CIR.0000015854.60710.10 DO - 10.1161/01.CIR.0000015854.60710.10 ID - Rajagopalan2002 ER - TY - JOUR AU - Takai, S. AU - Jin, D. AU - Muramatsu, M. AU - Kirimura, K. AU - Sakonjo, H. AU - Miyazaki, M. PY - 2005 DA - 2005// TI - Eplerenone inhibits atherosclerosis in nonhuman primates JO - Hypertension VL - 46 UR - https://doi.org/10.1161/01.HYP.0000184640.81730.22 DO - 10.1161/01.HYP.0000184640.81730.22 ID - Takai2005 ER - TY - JOUR AU - Mueller, K. B. AU - Bender, S. B. AU - Hong, K. AU - Yang, Y. AU - Aronovitz, M. AU - Jaisser, F. PY - 2015 DA - 2015// TI - Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure JO - Hypertension VL - 66 UR - https://doi.org/10.1161/HYPERTENSIONAHA.115.06172 DO - 10.1161/HYPERTENSIONAHA.115.06172 ID - Mueller2015 ER - TY - JOUR AU - Min, L. J. AU - Mogi, M. AU - Li, J. M. AU - Iwanami, J. AU - Iwai, M. AU - Horiuchi, M. PY - 2005 DA - 2005// TI - Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells JO - Circ Res VL - 97 UR - https://doi.org/10.1161/01.RES.0000180753.63183.95 DO - 10.1161/01.RES.0000180753.63183.95 ID - Min2005 ER - TY - JOUR AU - Callera, G. E. AU - Touyz, R. M. AU - Tostes, R. C. AU - Yogi, A. AU - He, Y. AU - Malkinson, S. PY - 2005 DA - 2005// TI - Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src JO - Hypertension VL - 45 UR - https://doi.org/10.1161/01.HYP.0000154365.30593.d3 DO - 10.1161/01.HYP.0000154365.30593.d3 ID - Callera2005 ER - TY - JOUR AU - Tatsumoto, N. AU - Yamada, S. AU - Tokumoto, M. AU - Eriguchi, M. AU - Noguchi, H. AU - Torisu, K. PY - 2015 DA - 2015// TI - Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification JO - Am J Physiol Renal Physiol VL - 309 ID - Tatsumoto2015 ER - TY - JOUR AU - Galmiche, G. AU - Pizard, A. AU - Gueret, A. AU - Moghrabi, S. AU - Ouvrard-Pascaud, A. AU - Berger, S. PY - 2014 DA - 2014// TI - Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness JO - Hypertension VL - 63 UR - https://doi.org/10.1161/HYPERTENSIONAHA.113.01967 DO - 10.1161/HYPERTENSIONAHA.113.01967 ID - Galmiche2014 ER - TY - JOUR AU - Papadimitriou, M. AU - Vyzantiadis, A. AU - Milionis, A. AU - Memmos, D. AU - Metaxas, P. PY - 1983 DA - 1983// TI - The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation JO - Life Support Syst VL - 1 ID - Papadimitriou1983 ER - TY - JOUR AU - Saudan, P. AU - Mach, F. AU - Perneger, T. AU - Schnetzler, B. AU - Stoermann, C. AU - Fumeaux, Z. PY - 2003 DA - 2003// TI - Safety of low-dose spironolactone administration in chronic haemodialysis patients JO - Nephrol Dial Transplant VL - 18 UR - https://doi.org/10.1093/ndt/gfg388 DO - 10.1093/ndt/gfg388 ID - Saudan2003 ER - TY - JOUR AU - Hussain, S. AU - Dreyfus, D. E. AU - Marcus, R. J. AU - Biederman, R. W. AU - McGill, R. L. PY - 2003 DA - 2003// TI - Is spironolactone safe for dialysis patients? JO - Nephrol Dial Transplant VL - 18 UR - https://doi.org/10.1093/ndt/gfg413 DO - 10.1093/ndt/gfg413 ID - Hussain2003 ER - TY - JOUR AU - Gross, E. AU - Rothstein, M. AU - Dombek, S. AU - Juknis, H. I. PY - 2005 DA - 2005// TI - Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients JO - Am J Kidney Dis VL - 46 UR - https://doi.org/10.1053/j.ajkd.2005.03.005 DO - 10.1053/j.ajkd.2005.03.005 ID - Gross2005 ER - TY - JOUR AU - Shavit, L. AU - Neykin, D. AU - Lifschitz, M. AU - Slotki, I. PY - 2011 DA - 2011// TI - Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study JO - Clin Nephrol VL - 76 UR - https://doi.org/10.5414/CN106973 DO - 10.5414/CN106973 ID - Shavit2011 ER - TY - JOUR AU - Walsh, M. AU - Manns, B. AU - Garg, A. X. AU - Bueti, J. AU - Rabbat, C. AU - Smyth, A. PY - 2015 DA - 2015// TI - The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial JO - Clin J Am Soc Nephrol VL - 10 UR - https://doi.org/10.2215/CJN.12371214 DO - 10.2215/CJN.12371214 ID - Walsh2015 ER - TY - JOUR AU - Taheri, S. AU - Mortazavi, M. AU - Shahidi, S. AU - Pourmoghadas, A. AU - Garakyaraghi, M. AU - Seirafian, S. PY - 2009 DA - 2009// TI - Spironolactone in chronic hemodialysis patients improves cardiac function JO - Saudi J Kidney Dis Transpl VL - 20 ID - Taheri2009 ER - TY - JOUR AU - McGill, R. L. AU - Biederman, R. W. AU - Getts, R. T. AU - Hazlett, S. M. AU - Sharma, S. B. AU - Duran, J. PY - 2009 DA - 2009// TI - Cardiac magnetic resonance imaging in hemodialysis patients JO - J Nephrol VL - 22 ID - McGill2009 ER - TY - JOUR AU - Flevari, P. AU - Kalogeropoulou, S. AU - Drakou, A. AU - Leftheriotis, D. AU - Panou, F. AU - Lekakis, J. PY - 2013 DA - 2013// TI - Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients JO - J Hypertens VL - 31 UR - https://doi.org/10.1097/HJH.0b013e32835f955c DO - 10.1097/HJH.0b013e32835f955c ID - Flevari2013 ER - TY - JOUR AU - Feniman-De-Stefano, G. M. AU - Zanati-Basan, S. G. AU - Stefano, L. M. AU - Xavier, P. S. AU - Castro, A. D. AU - Caramori, J. C. PY - 2015 DA - 2015// TI - Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients JO - Ther Adv Cardiovasc Dis VL - 9 UR - https://doi.org/10.1177/1753944715591448 DO - 10.1177/1753944715591448 ID - Feniman-De-Stefano2015 ER - TY - JOUR AU - Matsumoto, Y. AU - Mori, Y. AU - Kageyama, S. AU - Arihara, K. AU - Sugiyama, T. AU - Ohmura, H. PY - 2014 DA - 2014// TI - Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients JO - J Am Coll Cardiol VL - 63 UR - https://doi.org/10.1016/j.jacc.2013.09.056 DO - 10.1016/j.jacc.2013.09.056 ID - Matsumoto2014 ER - TY - JOUR AU - Matsumoto, Y. AU - Kageyama, S. AU - Yakushigawa, T. AU - Arihara, K. AU - Sugiyama, T. AU - Mori, Y. PY - 2009 DA - 2009// TI - Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients JO - Cardiology VL - 114 UR - https://doi.org/10.1159/000210553 DO - 10.1159/000210553 ID - Matsumoto2009 ER - TY - JOUR AU - Lin, C. AU - Zhang, Q. AU - Zhang, H. AU - Lin, A. PY - 2016 DA - 2016// TI - Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study JO - J Clin Hypertens (Greenwich) VL - 18 UR - https://doi.org/10.1111/jch.12628 DO - 10.1111/jch.12628 ID - Lin2016 ER - TY - JOUR AU - Nitta, K. AU - Akiba, T. AU - Nihei, H. PY - 2003 DA - 2003// TI - Aldosterone blockade and vascular calcification in hemodialysis patients JO - Am J Med VL - 115 UR - https://doi.org/10.1016/S0002-9343(03)00293-6 DO - 10.1016/S0002-9343(03)00293-6 ID - Nitta2003 ER - TY - JOUR AU - Vukusich, A. AU - Kunstmann, S. AU - Varela, C. AU - Gainza, D. AU - Bravo, S. AU - Sepulveda, D. PY - 2010 DA - 2010// TI - A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients JO - Clin J Am Soc Nephrol VL - 5 UR - https://doi.org/10.2215/CJN.09421209 DO - 10.2215/CJN.09421209 ID - Vukusich2010 ER - TY - JOUR AU - Hausmann, M. J. AU - Liel-Cohen, N. PY - 2002 DA - 2002// TI - Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function JO - Nephrol Dial Transplant VL - 17 UR - https://doi.org/10.1093/ndt/17.11.2035 DO - 10.1093/ndt/17.11.2035 ID - Hausmann2002 ER - TY - JOUR AU - Taheri, S. AU - Mortazavi, M. AU - Pourmoghadas, A. AU - Seyrafian, S. AU - Alipour, Z. AU - Karimi, S. PY - 2012 DA - 2012// TI - A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis JO - Saudi J Kidney Dis Transpl VL - 23 ID - Taheri2012 ER - TY - JOUR AU - Yongsiri, S. AU - Thammakumpee, J. AU - Prongnamchai, S. AU - Tengpraettanakorn, P. AU - Chueansuwan, R. AU - Tangjaturonrasme, S. PY - 2015 DA - 2015// TI - Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients JO - Ther Apher Dial VL - 19 UR - https://doi.org/10.1111/1744-9987.12219 DO - 10.1111/1744-9987.12219 ID - Yongsiri2015 ER - TY - JOUR AU - Ito, Y. AU - Mizuno, M. AU - Suzuki, Y. AU - Tamai, H. AU - Hiramatsu, T. AU - Ohashi, H. PY - 2014 DA - 2014// TI - Long-term effects of spironolactone in peritoneal dialysis patients JO - J Am Soc Nephrol VL - 25 UR - https://doi.org/10.1681/ASN.2013030273 DO - 10.1681/ASN.2013030273 ID - Ito2014 ER - TY - JOUR AU - Devuyst, O. AU - Margetts, P. J. AU - Topley, N. PY - 2010 DA - 2010// TI - The pathophysiology of the peritoneal membrane JO - J Am Soc Nephrol VL - 21 UR - https://doi.org/10.1681/ASN.2009070694 DO - 10.1681/ASN.2009070694 ID - Devuyst2010 ER - TY - JOUR AU - Williams, J. D. AU - Topley, N. AU - Craig, K. J. AU - Mackenzie, R. K. AU - Pischetsrieder, M. AU - Lage, C. PY - 2004 DA - 2004// TI - The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane JO - Kidney Int VL - 66 UR - https://doi.org/10.1111/j.1523-1755.2004.00747.x DO - 10.1111/j.1523-1755.2004.00747.x ID - Williams2004 ER - TY - JOUR AU - Vriese, A. S. AU - Flyvbjerg, A. AU - Mortier, S. AU - Tilton, R. G. AU - Lameire, N. H. PY - 2003 DA - 2003// TI - Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane JO - J Am Soc Nephrol VL - 14 UR - https://doi.org/10.1097/01.ASN.0000055652.37763.F7 DO - 10.1097/01.ASN.0000055652.37763.F7 ID - Vriese2003 ER - TY - JOUR AU - Davies, S. J. PY - 2004 DA - 2004// TI - Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients JO - Kidney Int VL - 66 UR - https://doi.org/10.1111/j.1523-1755.2004.66021.x DO - 10.1111/j.1523-1755.2004.66021.x ID - Davies2004 ER - TY - JOUR AU - Selgas, R. AU - Fernandez-Reyes, M. J. AU - Bosque, E. AU - Bajo, M. A. AU - Borrego, F. AU - Jimenez, C. PY - 1994 DA - 1994// TI - Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study JO - Am J Kidney Dis VL - 23 UR - https://doi.org/10.1016/S0272-6386(12)80814-6 DO - 10.1016/S0272-6386(12)80814-6 ID - Selgas1994 ER - TY - JOUR AU - Peso, G. AU - Fernandez-Reyes, M. J. AU - Hevia, C. AU - Bajo, M. A. AU - Castro, M. J. AU - Cirugeda, A. PY - 2005 DA - 2005// TI - Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor JO - Nephrol Dial Transplant VL - 20 UR - https://doi.org/10.1093/ndt/gfh793 DO - 10.1093/ndt/gfh793 ID - Peso2005 ER - TY - JOUR AU - Davies, S. J. AU - Bryan, J. AU - Phillips, L. AU - Russell, G. I. PY - 1996 DA - 1996// TI - Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis JO - Nephrol Dial Transplant VL - 11 UR - https://doi.org/10.1093/oxfordjournals.ndt.a027318 DO - 10.1093/oxfordjournals.ndt.a027318 ID - Davies1996 ER - TY - JOUR AU - Williams, J. D. AU - Craig, K. J. AU - Topley, N. AU - Ruhland, C. AU - Fallon, M. AU - Newman, G. R. PY - 2002 DA - 2002// TI - Morphologic changes in the peritoneal membrane of patients with renal disease JO - J Am Soc Nephrol VL - 13 ID - Williams2002 ER - TY - JOUR AU - Sawai, A. AU - Ito, Y. AU - Mizuno, M. AU - Suzuki, Y. AU - Toda, S. AU - Ito, I. PY - 2011 DA - 2011// TI - Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients JO - Nephrol Dial Transplant VL - 26 UR - https://doi.org/10.1093/ndt/gfq702 DO - 10.1093/ndt/gfq702 ID - Sawai2011 ER - TY - JOUR AU - Nishimura, H. AU - Ito, Y. AU - Mizuno, M. AU - Tanaka, A. AU - Morita, Y. AU - Maruyama, S. PY - 2008 DA - 2008// TI - Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model JO - Am J Physiol Renal Physiol VL - 294 UR - https://doi.org/10.1152/ajprenal.00565.2007 DO - 10.1152/ajprenal.00565.2007 ID - Nishimura2008 ER - TY - JOUR AU - Zhang, L. AU - Hao, J. B. AU - Ren, L. S. AU - Ding, J. L. AU - Hao, L. R. PY - 2014 DA - 2014// TI - The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis JO - Lab Invest VL - 94 UR - https://doi.org/10.1038/labinvest.2014.69 DO - 10.1038/labinvest.2014.69 ID - Zhang2014 ER - TY - JOUR AU - Yelken, B. AU - Gorgulu, N. AU - Gursu, M. AU - Yazici, H. AU - Caliskan, Y. AU - Telci, A. PY - 2014 DA - 2014// TI - Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients JO - Adv Perit Dial VL - 30 ID - Yelken2014 ER - TY - JOUR AU - Vazquez-Rangel, A. AU - Soto, V. AU - Escalona, M. AU - Toledo, R. G. AU - Castillo, E. A. AU - Polanco Flores, N. A. PY - 2014 DA - 2014// TI - Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial JO - Am J Kidney Dis VL - 63 UR - https://doi.org/10.1053/j.ajkd.2014.01.426 DO - 10.1053/j.ajkd.2014.01.426 ID - Vazquez-Rangel2014 ER -